Authors: Philip E. Cryer, Lloyd Axelrod, Ashley B. Grossman, Simon R. Heller, Victor M. Montori, Elizabeth R. Seaquist, and F. John Service Co-sponsoring Associations: American Diabetes Association, European Association for the Study <strong>of</strong> Diabetes, and European Society <strong>of</strong> Endocrinology Affiliations: Washington University School <strong>of</strong> Medicine (P.E.C.), St. Louis, Missouri; Massachusetts General Hospital and Harvard Medical School (L.A.), Boston, Massachusetts; Barts and the London School <strong>of</strong> Medicine, Queen Mary University <strong>of</strong> London (A.B.G.), London, United Kingdom; University <strong>of</strong> Sheffield (S.R.H.), Sheffield, United Kingdom; University <strong>of</strong> Minnesota (E.R.S.), Minneapolis, Minnesota; and Mayo Clinic (V.M.M., F.J.S.), Rochester, Minnesota Disclaimer Statement: Clinical Practice Guidelines are developed to be <strong>of</strong> assistance to endocrinologists by providing guidance and recommendations for particular areas <strong>of</strong> practice. The Guidelines should not be considered inclusive <strong>of</strong> all proper approaches or methods, or exclusive <strong>of</strong> others. The Guidelines cannot guarantee any specific outcome, nor do they establish a standard <strong>of</strong> care. The Guidelines are not intended to dictate the treatment <strong>of</strong> a particular patient. Treatment decisions must be made based on the independent judgment <strong>of</strong> health care providers and each patient’s individual circumstances. The Endocrine Society makes no warranty, express or implied, regarding the Guidelines and specifically excludes any warranties <strong>of</strong> merchantability and fitness for a particular use or purpose. The Society shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use <strong>of</strong> the information contained herein. Evidence-based reviews for this guideline were prepared under contract with The Endocrine Society. First published in the Journal <strong>of</strong> Clinical Endocrinology & Metabolism, March 2009, 94(3): 709-728 © The Endocrine Society, 2009
The Endocrine Society’s CLINICAL GUIDELINES <strong>Evaluation</strong> and <strong>Management</strong> <strong>of</strong> <strong>Adult</strong> <strong>Hypoglycemic</strong> <strong>Disorders</strong>: An Endocrine Society Clinical Practice Guideline
- Page 1: The Endocrine Society’s CLINICAL
- Page 5 and 6: Abstract Objective: The aim is to p
- Page 7 and 8: management (supported by education
- Page 9 and 10: continued glucose metabolism by the
- Page 11 and 12: TABLE 1. Causes of hypoglycemia in
- Page 13 and 14: 250,000 patient-years (40). It may
- Page 15 and 16: the appropriate tests have not been
- Page 17 and 18: TABLE 5. Suggested protocol for a m
- Page 19 and 20: counterregulation in most affected
- Page 21 and 22: prevalence of severe hypoglycemia w
- Page 23 and 24: 3.2. Evidence Randomized controlled
- Page 25 and 26: trained in, and dedicated to, trans
- Page 27 and 28: 3.7. Evidence Hypoglycemia causes f
- Page 29 and 30: 28. Nauck MA, Reinecke M, Perren A,
- Page 31 and 32: 82. Jackson JE 2005 Angiography and
- Page 33 and 34: 131. Ohkubo Y, Kishikawa H, Araki E
- Page 35 and 36: 183. ter Braak EW, Evers IM, Willem
- Page 37 and 38: THE ENDOCRINE SOCIETY GUIDELINE ORD
- Page 39 and 40: Commercial Reprint Information For
Change language